Ambros Therapeutics, Inc.
PrivateLast Round
Series A
Dec 16, 2025
Total Funding Raised
$125M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Ambros Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need, with its lead program targeting complex regional pain syndrome type 1 (CRPS-1).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ambros Therapeutics, Inc. Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Ambros Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 16, 2025 |
Key People
Founding team and executive leadership
Ambros Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Enavate Sciences | Series A |
| Janus Henderson Group | Series A |
| Balyasny Asset Management L.P. | Series A |
| RA Capital Management | Series A |
| Adage Capital Partners, L.P. | Series A |
| Adage Capital Management | Series A |
| Transhuman Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 2, 2026
Grew 16% QoQ, from 25 to 29 employees.
- May 3, 2026
Grew 45% QoQ, from 20 to 29 employees.
Ambros Therapeutics, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ambros Therapeutics, Inc.'s valuation, stock price, and market status.